Nav: Home

Researchers: Testosterone treatment effective for older men

February 18, 2016

As men age, their sexual function, vitality and strength can decline, but researchers had not yet established whether testosterone treatment is actually beneficial. Now, a team that included UF Health researchers has established testosterone's benefits in a study published yesterday (Feb. 17, 2016) in the New England Journal of Medicine.

The paper examines the first three of seven trials in a long-term study called The Testosterone Trials, or the TTrials. In this first study, researchers analyzed the results of the first three trials, which examined sexual function, physical function and vitality, including mood and depressive symptoms, walking speed and walking distance.

The researchers found that the treatment increased the blood testosterone level from moderately low to mid-normal in men ages 19-40 and improved all aspects of sexual function, including sexual activity, sexual desire and the ability to get an erection.

"The study reinforced the results we expected to see, except for walking speed," said Marco Pahor, M.D., the director of the UF Institute on Aging and a co-author of the paper.

In 2003, the Institute of Medicine reported there was not enough evidence to support a beneficial effect of testosterone in men who have low levels of the hormone. This report was the impetus for the TTrials, which are now the largest trials to examine the use of testosterone treatment in men 65 and older whose low testosterone levels can be attributed to age alone.

"The results of the TTrials show for the first time that testosterone treatment of older men who have unequivocally low testosterone levels does have some benefit," said Peter J. Snyder, M.D., the principal investigator of the TTrials and a professor in the division of endocrinology, diabetes and metabolism at the University of Pennsylvania's Perelman School of Medicine. "However, decisions about testosterone treatment for these men will also depend on the results of four other trials -- Cognitive Function, Bone, Cardiovascular and Anemia -- and the risks of testosterone treatment."

Researchers screened 51,085 men and found 790 who had a sufficiently low testosterone level to be part of the study. The subjects were randomized into two groups: one that applied a daily testosterone gel and the other a daily placebo gel, for one year. The researchers evaluated participants at three, six, nine and 12 months, assessing their sexual function with questionnaires; physical function with questionnaires and the distance walked in six minutes; and vitality, mood and depressive symptoms using questionnaires.

Across the three trials, adverse events including heart attack, stroke, other cardiovascular events and prostate conditions were similar in men who received testosterone and those who received a placebo. However, the number of men in the TTrials was too small to draw conclusions about the risk of testosterone treatment.

"A larger and longer-term trial will be needed to have more definitive results regarding safety," Pahor said. "However, this trial did not confirm earlier, smaller trials that raised serious concerns regarding cardiovascular safety."
-end-
The TTrials were conducted at UF and the Perelman School of Medicine at the University of Pennsylvania as well as 11 other sites, including Albert Einstein College of Medicine, Baylor College of Medicine, Brigham and Women's Hospital, Harbor-UCLA Medical Center, University of Alabama at Birmingham, Northwestern University Feinberg School of Medicine, Puget Sound Health Care System, University of California at San Diego School of Medicine, University of Minnesota School of Medicine, University of Pittsburgh School of Public Health and Yale School of Medicine.

The TTrials were supported by grant U01 AG030644 from the National Institute on Aging and the National Institutes of Health. The TTrials were also supported by the National Heart, Lung and Blood Institute; the National Institute of Neurological Diseases and Stroke; and the National Institute of Child Health and Human Development. AbbVie, formerly Solvay and Abbott Laboratories, also provided funding, AndroGel and placebo gel.

University of Florida

Related Testosterone Articles:

Women with asthma appear more likely to have lower levels of testosterone
Women with asthma appear more likely to have lower levels of 'free' (not attached to proteins) testosterone than women who do not have asthma, according to new research published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.
Penis development needs more than just testes and testosterone
Proper development of the fetal penis requires not just testosterone from the testes, but a second hormone produced by other tissues, including the placenta, according to a new study publishing Feb.
Testosterone treatment over 10 years can improve or reverse type 2 diabetes in men with low testosterone, and induce significant weight loss
New research presented at this year's annual meeting of the European Association for the Study of Diabetes (EASD) reveals that in men with low testosterone who have type 2 diabetes (T2D), testosterone therapy can improve their disease and reverse its progress, and can also induce significant weight loss.
Testosterone replacement therapy may slow the progression of COPD
GALVESTON, Texas -- Researchers from The University of Texas Medical Branch at Galveston found that testosterone replacement therapy may slow disease progression of chronic obstructive pulmonary disease.
Testosterone research brings new hope for cancer patients
Approximately 20 percent of cancer related deaths are attributed to the syndrome of cachexia.
More Testosterone News and Testosterone Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...